Introduction
Secondary prevention is emphasised in the European treatment guidelines for management of coronary heart disease (CHD) (Pyo Èra Èla È et al, 1994) , that is patients with established CHD should have the highest priority in clinical practice. Diet therapy forms an essential part of cholesterol lowering in CHD patients, and besides its cholesterol lowering properties a fat modi®ed diet may have bene®cial effects on weight, blood pressure and clotting factors (Ulbricht & Southgate, 1991; Simon et al, 1996) .
Studies on adherence to the cholesterol lowering diet in free-living CHD patients receiving usual care are rare. On the contrary, several clinical trials to lower successfully cholesterol with the aid of a diet modi®cation have been carried out. However, Ramsay and his coworkers (Ramsay et al, 1991) have doubted the ef®ciency of dietary modi®cation to lower serum cholesterol. A basis for this mistrust could be that the adherence to the dietary goals has been poor in the studies included in their review. Generally, the mean intakes of fat and saturated fat have been above the recommended levels in CHD patients analyzed in a prospective cohort (Allen & Blumenthal, 1995) , in population based surveys (Fehily et al, 1987; Bolton-Smith et al, 1992) or in the baseline phase of trials (Karvetti, 1981; Fehily et al, 1989; Shenberger et al, 1992; Watts et al, 1994) . Earlier studies have included mainly patients with myocardial infarction or angina except for the studies performed on patients with coronary artery bypass grafting (Allen & Blumenthal, 1995; Shenberger et al, 1992) . A question remains whether the severity of CHD or the coexistence of other chronic diseases would be associated with concordance of diet with the recommended one.
The purpose of this study, which was carried out as a part of the Finnish contribution to the EUROASPIRE study (European Action on Secondary Prevention by Intervention to Reduce Events) (EUROASPIRE Study Group, 1997) , was to examine the concordance of diet with the recommended cholesterol lowering diet in four patient groups divided according to the severity of CHD: patients with coronary bypass grafting, percutaneous transluminal angioplasty, acute myocardial infarction or acute myocardial ischemia. Food records and serum lipid fatty acids were used to estimate dietary intake. Group, 1997 ) was a survey on the management of risk factors and the use of cardiovascular drugs in secondary prevention of CHD carried out upon the initiative of the Working Group on Epidemiology and Prevention of the European Society of Cardiology in nine centres in different European countries (Czech Republic, Finland, France, Germany, Hungary, Italy, Netherlands, Slovenia and Spain) . According to the EUROASPIRE study protocol consecutive male and female patients with CHD aged under 71 y were identi®ed from the hospital discharge lists and coronary angiography register of the Kuopio University Hospital from the following four diagnostic categories:
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1. patients with their ®rst elective or emergency coronary artery bypass grafting (CABG) 2. patients with their ®rst elective or emergency percutaneous transluminal coronary angioplasty (PTCA) but with no previous CABG 3. patients with their ®rst or recurrent acute myocardial infarction (AMI) but with no previous CABG or PTCA 4. patients with acute myocardial ischemia (AMIS) but no evidence of AMI and no previous CABG, PTCA or AMI.
Consecutive patients hospitalized before 1 November 1994 were identi®ed from the registers chronologically in reverse order in order to get 125 patients for each diagnostic category except 150 for AMI category because of high expected mortality in this patient group. Following the EUROASPIRE study protocol, surviving patients were invited for an interview and examination at least six months after hospitalization. In Finland this phase of the study was performed between 1 June 1995 and 31 October 1995. The time interval between hospital admission and the interview was 1.0 (0.8±1.3), 1.9 (0.9±4.0), 2.3 (0.9±3.7) and 2.2 (1.0±3.8) y [median, (range)] in the patient groups, respectively. From the four patient groups 109, 106, 101 and 99 patients participated in the interview and examination, respectively. The corresponding participation rates were 88, 88, 74 and 79%. The ages were 61.0 AE 8.1 and 59.9 AE 9.8 y for responders and non-responders, respectively. Of the responders 68.7% were men and of the non-responders 60.4%.
Food records
Patients completed a four-day food record (three weekdays and one weekend day) at home according to the detailed written instructions. The amount of food was estimated using a portion size booklet (National Health Institute). Patients returned food records at the interview and all the records were checked by a clinical nutritionist, and if necessary missing information was added. The nutrient intake was calculated from food records using MicroNutrica 1 dietary analysis program (version 2.0, Finnish Social Insurance Institute, Turku, Finland) based on the national database of the Finnish Social Insurance Institute.
Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension were used as a reference for a cholesterol lowering diet (Pyo Èra Èla È et al, 1994) . These recommendations accord with the ones of National Cholesterol Education Program (National Cholesterol Education Program, 1994) . The intake of total fat should be 30% or less of total calories, saturated fat a third or less of the total fat intake (equals to 10 E% or less) and cholesterol less than 300 mg/d. European recommendations do not specify a goal for ®ber intake, but they refer to the recommendations of WHO Study Group (Report of a WHO Study Group, 1990 ) 27 g/d or more, which is used in this study as a recommended intake.
Risk factor measurements
Patient's height and weight were measured, and body mass index (BMI, kg/m 2 ) was calculated. Blood pressure was measured with an automatic digital sphygmomanometer. Data on previous AMI, current medication use and smoking were obtained by an interview. Non-smoking was also validated with a breath carbon monoxide measurement ( 10 ppm). Patients were classi®ed as a diabetic if the diagnosis of diabetes had previously been con®rmed by a physician. Data on lifestyle and nutritional counselling before and after the hospitalization were obtained from medical records. Blood samples were collected between 8.00±10.00 after a 12 h fast for the analysis of serum total cholesterol, HDL cholesterol and triglycerides and fatty acid composition of serum lipids. Standardized, entsymatic methods were used for the analysis of serum lipids.
Fatty acid composition of serum lipids
Serum samples for the analysis of fatty acid composition were stored at 770 C until analyzed. Lipids were extracted from serum sample (100 ml) with chloroform-methanol (2:1) (A Ê gren et al, 1992) . Lipid fractions [cholesterol esters (CE), triglycerides (TG) and phospholipids (PL)] were then separated with an aminopropyl column. Fatty acids of lipid fractions were transmethylated with 14% borontri¯uoride in methanol at 100 C for 1 h. Finally, fatty acid methyl esters were analyzed with gas-chromatograph (Hewlett-Packard 5890 series II, Hewlett-Packard Company, Waldbronn, Germany) equipped with FFAP-column (length 25 m, inner diameter 2 mm and ®lm thickness 0.3 mm) helium as a carrier gas. Fatty acids are presented as molar percentage of total fatty acids. Heptadecanoate acid (17:0) was used as an internal standard in every sample analyzed to quantify the fatty acids.
The study was approved by the Ethics Committee at the University of Kuopio. All patients gave their informed consent for the study.
Statistical methods
Statistical analyses were performed using SPSS for Windows program (version 6.0.1, SPSS Inc., Chicago, USA). Normal distribution of variables was checked with Kolmogorov±Smirnov test, and log-transformation was used for those not normally distributed. Differences in patient characteristics, energy and nutrition intake and serum lipid fatty acids were tested by analysis of variance when comparing the patient groups. t-Test for independent samples was used to compare intake of fat and saturated fat in secondary subgroups (diabetic and obese patients or those with previous AMI). In multiple comparisons t-tests with correction of Bonferroni were used. Analysis of covariance was used to test differences in intake of fat and saturated fat between users and non-users of lipid-lowering drugs and also to test the associations of dietary saturated fat intake and serum lipid fatty acid composition. Differences among the patient groups in the proportions of patients who achieved the recommended nutrient intake or had a certain risk factor were tested by w 2 -test. The results for continuous variables are expressed as means AE s.d. P value of`0.05 was considered statistically signi®cant.
Results
The basic characteristics of the patients in four groups are shown in Table 1 . Patient's mean age at the time of interview was 61 y (range 33±74), patients with PTCA were younger than the others. The mean BMI was 28.2 AE 4.0 kg/m (mean AE s.d.). Patients with revascularisation procedures used more frequently lipid lowering drugs than patients with AMI or AMIS. The prevalence of diabetes or obesity (!30 kg/m 2 ) was similar among the patient groups. There were no differences among the patient groups in the received nutritional and lifestyle counselling due to obesity, hypertension or hyperlipidaemia according to medical records.
There were no differences in the intake of energy, energy nutrients or dietary cholesterol among the patients groups (Table 2) . Fiber intake, both as grams per day or energy-adjusted, was higher in patients with CABG than in patients with AMIS. The proportion of saturated fatty acids from total fatty acids was 42% and it was similar in all patient groups.
Of the whole study group 35% had fat intake below 30 E%, while only 25% met the recommendation for saturated fat intake ( Figure 1 ). The recommended cholesterol intake (`300 mg/d) was achieved by the majority (83%) of the patients. The recommended ®ber intake (b 27 g/d) was met by 22% of the patients. However, using energy-adjusted values of cholesterol and ®ber intake 26% and 53% achieved the recommendations, respectively (cholesterol`100 mg/4.18 MJ, ®ber b 12 g/ 4.18 MJ). There were no statistically signi®cant differences among the patient groups in concordance with any of these dietary recommendations.
The fatty acid composition of serum TG, CE and PL is shown in Table 3 . In general, there were no major differ- ences in serum lipid fatty acids among the patient groups. However, myristic acid in all lipid fractions was higher in patients with AMIS than in others. Oleic acid in TG was higher in patients with PTCA than in patients with AMI or AMIS. g-linolenic acid in TG and PL was lower in patients with CABG than in others. a-linolenic acid in CE and PL was also lower in patients with CABG than with AMIS. In patients with CABG docosapentanoic acid in TG was lower than in others and in PL lower than in patients with AMI. Concordance of patients' diet with the dietary recommendations was also evaluated according to some clinical characteristics in the whole study population. As lipid lowering drug usage differed among the patient groups concordance was analyzed the patient group as a covariate. Concordance with the recommended fat and saturated fat intake was better in patients who use lipid lowering drugs than in non-users (Table 4) . Myristic acid in TG (3.09 AE 1.13 vs 2.83 AE 0.87, P 0.014) and PL (0.64 AE 0.18 vs 0.60 AE 0.16, P 0.04) and palmitic acid in TG (29.58 AE 3.94 vs 28.50 AE 3.95, P 0.012) were higher in patients who did not use lipid lowering drugs compared to those who used. The higher proportion of saturated fatty acids in TG (36.68 AE 5.66 vs 35.20 AE 4.90, P 0.009) in patients who did not use lipid lowering drugs was accompanied by the lower proportion of monounsaturated fatty acids (44.04 AE 3.94 vs 45.11 AE 4.25, P 0.012). Of the patients who used lipid lowering drugs 2% had been given dietary advice by nutritionist and 25% had been given general lifestyle counselling by nursing staff. The corresponding ®gures for patients not using lipid lowering drugs were 4 and 24%.
Unexpectedly, diabetic patients tended to have a higher intake of saturated fat than non-diabetic patients. The intake of ®ber was lower in diabetics than in non-diabetics (20 vs 22 g/d, P 0.057). Diabetic patients had been given dietary and general lifestyle counselling more often than non-diabetic ones (dietary advice by nutritionist: 11 vs 1%, general lifestyle counselling by nursing staff 36 vs 23%). The intake of total fat did not differ, but that of saturated fat was lower in the patients whose BMI was`30 kg/m 2 than in those patients whose BMI was ! 30 kg/m 2 . Previous AMI did not have an effect on concordance with the recommended diet.
Data from all patients were combined for the analysis of associations of dietary saturated fat intake (E%) and serum lipid fatty acids (% mol), the analysis being adjusted for the patient group and sex. Myristic acid in TG, CE and PL was signi®cantly higher in patients in the highest tertile of dietary saturated fat intake than in the middle or the lowest tertile (Figure 2 ). Palmitic acid in TG was positively and linoleic acid in TG was negatively associated with dietary saturated fat intake. Palmitic and linoleic acids in CE and PL were not associated with saturated fat intake in this study.
Discussion
The purpose of this study was to evaluate the concordance of diet with the recommended cholesterol lowering diet in CHD patients by food records and fatty acid composition of serum lipids. Participation rate was good, 82% in the whole study. The sex and age of the patients who did not participate did not differ from those who did. The time interval between the hospital admission and interview differed among the patient groups because a longer time interval was needed to collect the designed number of consecutive patients with PTCA, AMI and AMIS than that of patients with CABG from the hospital registers.
We originally assumed that the operated patients might have a better concordance of diet with the recommended cholesterol lowering diet due to the severity of disease, better motivation and more frequent counselling, but there were no differences in concordance among the patient groups. The patients had been given the nutritional and lifestyle counselling that is included in the usual care in hospitals and health care centers by nurses, physicians and in some few cases by clinical nutritionists. Counselling in hospital did not differ among the patient groups according to medical records although it is possible that counselling has also been given elsewhere. Only one third of the whole study group met the recommended fat intake which is consistent with the ®ndings of Allen and Blumenthal (1995) , who reported that 36% of women after CABG had fat intake under 30 E%. While in the DART study Figure 1 Proportions of patients achieving the recommended intakes of fat, saturated fat (SAFA), cholesterol and ®ber in the patient groups analyzed with w 2 -test indicating no statistical differences among the groups. E%, percent of calories of total energy intake; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; AMI, acute myocardial infarction; AMIS, acute myocardial ischemia. (Fehily et al, 1989) only 21% of the men with AMI in a group which had not been given advice about fat intake achieved the recommended fat intake. In other studies the mean intake of fat has been far from recommended, even about 40 E% (Fehily et al, 1987; Bolton-Smith et al, 1992; Watts et al, 1994) .
In the present study to achieve the recommended saturated fat intake seemed to make the greatest demand on the patients. Dif®culties in achieving the recommended saturated fat intake have also been reported earlier in men with AMI or angina (Fehily et al, 1987; Bolton-Smith et al, 1992) . A low mean energy intake led to bias in the proportions of patients who achieved the dietary recommendations expressed as grams per day or as energy adjusted values. A low cholesterol intake, as milligrams per day, was achieved by the majority of the patients, but the corresponding energy-adjusted intake was ful®lled less often. Same kind of disagreement was observed in the intake of ®ber, the recommendation for ®ber as grams per day was achieved less often than the recommendation for energy-adjusted ®ber intake. However, it has been reported that underreporting does not necessarily distort the energy adjusted intakes of macronutrients in a dietary survey (Hirvonen et al, 1997) . In the present study cholesterol intake was 220 mg/d, which represents a low mean intake compared to previous studies where it has varied from 160 mg/d in women with CABG (Allen & Blumenthal, 1995) to 350 mg/d in men with angina or AMI (BoltonSmith et al, 1992; Watts et al, 1994) . The ®ber intake has varied from 14 g/d in women with CABG (Allen & Blumenthal, 1995) to 28 g/d in men with AMI or angina pectoris receiving dietary therapy (Watts et al, 1994) .
The total fat intake of CHD patients resembled that of Finnish men and women in 1992 (33 vs 34 E%), on the other hand, the intake of saturated fat was lower in these CHD patients than that of average population (13 vs 16 E%) (Pietinen et al, 1996) . This resemblance suggests that no marked dietary changes have been made or the changes made do not last for longer periods of time after the diagnosis of CHD. The patients who used lipid lowering drugs had lower fat and saturated fat intake than those not using such medication. This suggests that they were more motivated than other CHD patients to change their diet. Gender, obesity and nutritional and lifestyle counselling of the patients using lipid lowering drugs did not differ from that of non-users. However, patients who used lipid lowering drugs were younger than non-users. CHD patients with diabetes had somewhat higher intake of saturated fat, and lower intake of ®ber than non-diabetic patients even though those with diabetes had been given more frequently advice by a nutritionist or general lifestyle counselling. Diabetic and non-diabetic patients were similar in regard to age and sex distribution. Furthermore, they were equally distributed among the patient groups, but diabetic patients were more obese than their non-diabetic counterparts (BMI ! 30 kg/m 2 in 47% of diabetics vs in 27% of non-diabetics). Higher intakes than the recommended ones of total and saturated fat have been observed in NIDDM patients even after intensi®ed dietary counselling which, however, markedly could improve their dietary habits (Laitinen et al, 1993) .
The fatty acid composition of serum lipids re¯ects the fat quality of diet (Glatz et al, 1989; Bùnaa et al, 1992; Ma et al, 1995; Nikkari et al, 1995; Zock et al, 1997) . The proportion of linoleic acid in serum lipids has high positive correlations with dietary linoleic acid, polyunsaturated fatty acids as well as with dietary P:S ratio (ratio of polyunsaturated to saturated fatty acids (Glatz et al, 1989; Ma et al, 1995; Nikkari et al, 1995; Zock et al, 1997) . Also dietary intake of n-3 fatty acids is re¯ected in the proportions of eicosapentanoic and docosahexanoic acids in serum lipids (Bùnaa et al, 1992) . The differences in fatty acid composition of serum lipids among the patient groups were marginal and inconsistent except that myristic acid was higher in the patients with AMIS. Although myristic acid formed a minor part of dietary fat intake (1.4 E%), the proportion of myristic acid in serum lipids was a marker of saturated fat intake as reported earlier (Nikkari et al, 1995; Zock et al, 1997) . The principal source of myristic acid are dairy products in the Finnish diet (Pietinen et al, 1996; Pa Èivi Kleemola, personal communication, February, 1997) . Judging from the proportion of myristic acid in serum lipids, it seems that the patients with AMIS had a higher saturated fat intake but the food records were unable to detect this difference among the groups. However, there was a trend that AMIS patients had a higher dietary intake of fat and saturated fat. Otherwise, the results concerning the fatty acid composition of serum lipids were in accordance with the food diaries conveying that there were no other major differences in dietary fat quality among the patient groups.
Conclusions
Concordance of the diet with the recommended cholesterol lowering diet in CHD patients was moderate. Concordance was not affected by disease severity or previous myocardial infarction and was slightly worse in CHD patients who had diabetes or were obese or did not use lipid lowering drugs.
